Literature DB >> 11391689

Optimal continuous sequential boundaries for monitoring toxicity in clinical trials: a restricted search algorithm.

A I Goldman1, P J Hannan.   

Abstract

Continuous monitoring of severe adverse experiences can ensure the timely termination of a clinical trial if the therapy is shown to be harmful. In this paper we present methods for choosing a stopping rule for continuous monitoring of toxicity in small trials. They are especially useful for small phase II trials of about 30 patients for monitoring a binary toxicity event that is observed relatively quickly compared to the efficacy outcome. In 1987 Goldman described an algorithm for computing the exact type I error rate (alpha) and power (1-beta) of a specified discrete stopping boundary for sequential monitoring of a study with a fixed maximum number of patients (N) to be enrolled on the experimental therapy. Only an upper boundary was used since trials are only terminated for an excess frequency of toxicity and not for a low rate. By repeated use of this algorithm a stopping rule can be identified which has nearly the chosen level of (alpha) and a reasonable power depending on the design parameters of the study. The work reported here embeds this earlier algorithm as a subroutine in a larger FORTRAN program which searches all boundaries that fulfil constraints on size and power, as specified by the user. The search is restricted so that only those boundaries with size in a small neighbourhood of the chosen alpha are examined and displayed if the power is above a set minimum. These restrictions reduce the number of boundaries examined to only 0.4 per cent of all possible boundaries, thus reducing running time to a practical few seconds. Many such boundaries exist, the one with the largest power can then be chosen for monitoring the trial. The average sample number (ASN) and the expected relative loss (ERL) are also computed. The criterion for choosing may also be based on small ASN or low ERL in addition to power and appropriate alpha. Copyright 2001 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Year:  2001        PMID: 11391689     DOI: 10.1002/sim.713

Source DB:  PubMed          Journal:  Stat Med        ISSN: 0277-6715            Impact factor:   2.373


  6 in total

1.  Sequential generalized likelihood ratio tests for vaccine safety evaluation.

Authors:  Mei-Chiung Shih; Tze Leung Lai; Joseph F Heyse; Jie Chen
Journal:  Stat Med       Date:  2010-11-20       Impact factor: 2.373

Review 2.  Does concomitant acromioplasty facilitate arthroscopic repair of full-thickness rotator cuff tears? A meta-analysis with trial sequential analysis of randomized controlled trials.

Authors:  Lei Song; Ling Miao; Peng Zhang; Wen-Liang Wang
Journal:  Springerplus       Date:  2016-05-21

3.  Quantitative Framework for Retrospective Assessment of Interim Decisions in Clinical Trials.

Authors:  Roger Stanev
Journal:  Med Decis Making       Date:  2016-06-27       Impact factor: 2.583

4.  Accelerating clinical development of HIV vaccine strategies: methodological challenges and considerations in constructing an optimised multi-arm phase I/II trial design.

Authors:  Laura Richert; Adélaïde Doussau; Jean-Daniel Lelièvre; Vincent Arnold; Véronique Rieux; Amel Bouakane; Yves Lévy; Geneviève Chêne; Rodolphe Thiébaut
Journal:  Trials       Date:  2014-02-26       Impact factor: 2.279

5.  Safety monitoring in clinical trials.

Authors:  Bin Yao; Li Zhu; Qi Jiang; H Amy Xia
Journal:  Pharmaceutics       Date:  2013-01-17       Impact factor: 6.321

6.  Oral Motor Intervention Improved the Oral Feeding in Preterm Infants: Evidence Based on a Meta-Analysis With Trial Sequential Analysis.

Authors:  Xu Tian; Li-Juan Yi; Lei Zhang; Jian-Guo Zhou; Li Ma; Yang-Xiang Ou; Ting Shuai; Zi Zeng; Guo-Min Song
Journal:  Medicine (Baltimore)       Date:  2015-08       Impact factor: 1.889

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.